FDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (in 2026)
16.0 Pkt. (24h)GeopolitikOne-OffHealth & Medicine3Mon
KalshiVerfügbarkeit prüfenKYC erforderlich2% GebührVerifizierte AuflösungsdatenOrdentlich kalibriertAktuelle implizite Wahrscheinlichkeit
Ja 98%+16.0pt
Marktqualitat
44 / 100
Niedrige Qualität24h-Volumen
511 €
Liquidität
156,7 €
Niedrige LiquiditätGeld / Brief
80.0% / 88.0%
Spread
8.0 pt
Breiter SpreadMarktdaten
Aktualisiert vor 3 Minuten
17. Juni 26, 21:00 UTC1. Jan. 27, 04:59 UTC
Trends
Verwandte Märkte
Verwandte Fragen als Kontext, kein Vergleich gleichwertiger Kontrakte.
FDA decision: Bepirovirsen by GlaxoSmithKline (in 2026)
KalshiFDA decision: Saroglitazar by Zydus Therapeutics (in 2026)
KalshiFDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (in 2026)
KalshiDid COVID-19 come from a laboratory?
Manifold MarketsWhich states will report local cases in the May 2026 Ebola Bundibugyo outbreak
Manifold MarketsWhen, where or how will Trump die?
Manifold MarketsRegeln
If the FDA's decision on Ifinatamab Deruxtecan by Daiichi Sankyo in 2026 is a full approval or an accelerated approval, the market resolves to Yes.
Abwicklung über:AppliedXL
- This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.
- Ifinatamab deruxtecan (also called I-DXd or DS-7300) is an antibody-drug conjugate — think of it as a guided missile where a targeting protein is chemically linked to a potent cancer-killing payload.
- The targeting protein homes in on a molecule called B7-H3 (also known as CD276), which appears in unusually high amounts on the surface of many cancer cells, and once the drug locks onto that target it is pulled inside the cell and releases its toxic payload.
- In doing so, it aims to kill tumor cells more precisely than traditional chemotherapy, which attacks both healthy and cancerous cells indiscriminately.
Offene Märkte
Geopolitics
POLYMARKETWhich party will gain most seats in Russian Parliamentary Election?
- United Russia (ER)+5.0pt75%
- New People (NL)-4.1pt21%
- Liberal Democratic Party of Russia (LDPR)-1.1pt3%
+5 weitere Ergebnisse
- Gesamtvolumen
- 22,2 Mio. €
- 24h-Volumen
- 470.753,1 €
POLYMARKETUS announces end of Iranian blockade by which date?
- December 31-2.3pt48.3%
- October 31-2.0pt29.3%
- September 30-4.0pt12.1%
+17 weitere Ergebnisse
POLYMARKETUS x Iran Effective Ceasefire begins by...? (2 week pause)
- September 30+1.0pt80%
- September 18+1.0pt75%
- September 11+6.5pt70%
+2 weitere Ergebnisse
POLYMARKETWill China invade Taiwan by end of 2026?
- No-0.2pt96%
- Yes+0.2pt4%
- Gesamtvolumen
- 35,3 Mio. €
- 24h-Volumen
- 100.050,2 €
POLYMARKETIsrael x Iran ceasefire continues through which date?
- July 18+0.3pt100%
- July 20+0.1pt100%
- July 22+0.5pt100%
+20 weitere Ergebnisse
POLYMARKETKharg Island no longer under Iranian control by which date?
- December 317%
- September 30+0.1pt1%
- July 310%
+7 weitere Ergebnisse
- Gesamtvolumen
- Nobel Peace Prize Winner 2026
- US-Iran nuclear deal?
- Russia x Ukraine peace talks by which date?
- Strait of Hormuz traffic returns to normal by December 31?
- Will the U.S. invade Iran before 2027?
- Bab el-Mandeb Strait effectively closed by which date?
- What will Trump say during RNC Convention (Night 2)?
- Russia x Ukraine ceasefire agreement by which date?
- Iran-Oman Hormuz Management Agreement by which date?
- Will the Iranian regime fall by September 30?
Häufige Fragen
- Wie stehen die aktuellen Quoten für FDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (in 2026)?
- Kalshi bewertet Yes mit 98% (Stand: 8. September 2026).
- Wann wird FDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (in 2026) entschieden?
- FDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (in 2026) soll am 1. Januar 2027 entschieden werden.
- Wie wird FDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (in 2026) abgerechnet?
- Kalshi rechnet diesen Markt wie folgt ab: If the FDA's decision on Ifinatamab Deruxtecan by Daiichi Sankyo in 2026 is a full approval or an accelerated approval, the market resolves to Yes.